Recently, Cascade announced that the new FXR agonist CS0159 jointly developed by Eric Xu, the founder of the company, and Li Jia, the founder of the Shanghai Institute of Pharmacy, won the qualification of the Fast Track of the US Food and Drug Administration (FDA) for the treatment of patients with nonalcoholic steatohepatitis (NASH).
